Search the Newsreel

AQR group (VRXA) discloses 658,138-share Veraxa Biotech position under 5% threshold

AQR Capital Management, along with its affiliates, has reported a beneficial ownership of 658,138 Ordinary Shares in Veraxa Biotech Holding AG, which includes warrants. This position represents 0.46% of Veraxa’s outstanding Ordinary Shares, confirming that the AQR group holds less than the 5% threshold. …

Vera Therapeutics CEO Marshall Fordyce sells $679,747 in stock

Marshall Fordyce, CEO of Vera Therapeutics, sold $679,747 worth of Class A Common Stock on May 12, 2026, after exercising stock options. These transactions were executed under a pre-arranged trading plan, and he now directly owns 235,244 shares and holds 590,551 stock options. The …

Vera Therapeutics president and CEO Marshall Fordyce sells $1.96m in stock

Marshall Fordyce, President and CEO of Vera Therapeutics, Inc. (NASDAQ:VERA), sold 46,250 shares of the company’s Class A Common Stock for approximately $1.96 million on July 7, 2026, while concurrently acquiring the same number of shares through stock option exercises. The sales were conducted …

Vera Therapeutics (VERA) CEO trades 18,500 shares via 10b5-1 option exercise

Vera Therapeutics' President and CEO, Marshall Fordyce, exercised options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares on June 23, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on January …

Vera Therapeutics (VERA) CEO option exercise and 18,500-share sale under 10b5-1 plan

Vera Therapeutics (VERA) CEO Marshall Fordyce exercised stock options for 18,500 shares of Class A Common Stock at $2.8968 per share and subsequently sold all 18,500 shares in open-market transactions on May 12, 2026. The sales, totaling approximately $680K in gross proceeds, were executed …

Veranda Learning Solutions Q1 Results: Earnings call audio uploaded

Reasons Why Investors Can Consider Buying Veralto Stock Now

Veralto (VLTO) is presented as an attractive investment opportunity due to its impressive performance, solid Zacks Rank #2, positive earnings surprise history, and strong growth prospects. The company benefits from growth in U.S. infrastructure investments and rising semiconductor demand, with its Water Quality and …

Eastroc Beverage Sets Interim Dividend and Key Dates for 2026 Payout

Eastroc Beverage Calls August EGM on Payout Plans and H-Share Buyback Mandate

Veralto Corporation $VLTO Shares Acquired by Handelsbanken Fonder AB

Handelsbanken Fonder AB has increased its stake in Veralto Corporation (NYSE:VLTO) by 9.1% in Q2, bringing its total holdings to 219,254 shares valued at $19.4 million. Other institutional investors also adjusted their positions, with overall institutional ownership at 91.28%. Analysts maintain a "Moderate Buy" …

Veranda Learning Solutions reports consolidated net profit of Rs 29.12 crore in the June 2026 quarter

Bank of America Corp DE Grows Stock Position in Veracyte, Inc. $VCYT

Bank of America Corp DE increased its stake in Veracyte, Inc. by 14.7% in the first quarter, holding 1.45 million shares valued at $46.7 million. Other institutional investors also raised their positions, and analysts maintain a "Moderate Buy" rating with an average target price …

Veranda Learning Q1FY27 net profit up 471% to ₹339 crore

Vera Bradley (NASDAQ:VRA) Share Price Crosses Above 200 Day Moving Average - Time to Sell?

Vera Bradley (NASDAQ:VRA) shares recently crossed above their 200-day moving average, trading at $3.40 against an average of $3.39, but remained below their 50-day average. Analyst sentiment is cautious with a "Reduce" rating, despite the company beating Q1 earnings expectations with a smaller loss …

Projeções de Resultados: Monster Beverage Corp (MNST) — LPA e Crescimento de Receita

Veralto Corporation (1VLTO) Q1 2024 Earnings Report - Results, Call & Slides

Veralto Corporation (1VLTO) announced its Q1 2024 earnings, reporting an actual EPS of €0.73, beating the consensus of €0.66, and actual revenue of €1.08 billion, surpassing the expected €1.06 billion. The company's earnings call took place on April 23, 2024, and its next earnings …

Needham Maintains Veradermics(MANE.US) With Buy Rating, Maintains Target Price $164

Needham has reiterated its Buy rating for Veradermics (MANE.US) and maintained its price target of $164. This indicates continued confidence in the company's stock performance by the investment firm.

Veradermics, Inc SEC Filing (Aug 12, 2026)

This article details an SEC Form 144 filing by Veradermics, Inc. (MANE) on August 12, 2026. The filing indicates a proposed sale of 104,587 shares of common stock with an aggregate market value of $11,394,753.65 through Merrill Lynch. The shares were acquired via a …

How Investors May Respond To Veracyte (VCYT) Raising 2026 Revenue Guidance After Returning To Profit

Veracyte (VCYT) has raised its full-year 2026 revenue guidance to $590-$596 million and reported a return to profit in Q2 2026, with net income of $25.49 million. This improved outlook, driven by increasing test adoption, strengthens the company's investment narrative, although risks around reimbursement …

Las acciones de Monster Beverage (MNST) parecen estar cerca de su valor razonable, mientras que los resultados ya se reflejan en el precio

Monster Beverage (MNST) Stock Looks Near Fair Value While Earnings Price In More

Monster Beverage (MNST) stock appears to be near fair value according to a Discounted Cash Flow (DCF) model, despite trading roughly 7.8% above the DCF estimate. However, earnings-based multiples suggest the stock is overvalued, with a P/E ratio of 41.9x compared to the industry …

LiveRamp (RAMP) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong

A Look at Veracyte Inc (VCYT) After 3.7% Decline -- GF Value $38

Veracyte Inc (VCYT) shares recently declined by 3.7%, trading at $44.68, which is 15.6% above its GF Value™ estimate of $38.64, indicating it is "modestly overvalued." Despite a strong GF Score™ of 82/100, driven by high growth and financial strength, the company has a …

Precision Trading with Liveramp Holdings Inc. (RAMP) Risk Zones

Liveramp Holdings Inc. (RAMP) is showing neutral near and mid-term readings, potentially moderating a long-term positive bias, with an active mid-channel oscillation pattern. The article details three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, and highlights an exceptional …

Monster Beverage achieves monster results

Monster Beverage Corp. reported record financial results in its second quarter, surpassing $2.5 billion in net sales for the first time, with double-digit sales growth across all geographic regions. The company's innovative product lineup, including the successful Ultra Red, White and Blue limited-time beverage …

Veradermics: Q2 Earnings Snapshot

Veradermics Inc. (MANE) reported a significant loss of $23.5 million, or 58 cents per share, in its second quarter. The New Haven, Connecticut-based company's financial results were disclosed on Tuesday, August 11, 2026. This data was compiled by Automated Insights using information from Zacks …

Hennion & Walsh Asset Management Inc. Acquires 347,872 Shares of Verastem, Inc. $VSTM

Hennion & Walsh Asset Management Inc. significantly increased its stake in Verastem, Inc. (NASDAQ:VSTM) by 157.2%, acquiring an additional 347,872 shares, bringing their total ownership to 569,195 shares valued at $2.17 million. This move is part of broader institutional interest, with collective institutional ownership …

Pacer Advisors Inc. Has $364,000 Position in Molson Coors Beverage Company $TAP

Molson Coors Beverage Company $TAP Shares Acquired by Bank of America Corp DE

Amundi Sells 116,588 Shares of Veracyte, Inc. $VCYT

Amundi significantly reduced its stake in Veracyte, Inc. by selling 116,588 shares, a 90.6% decrease, though other institutional investors increased their holdings. Veracyte surpassed Q1 earnings and revenue estimates, reporting $0.54 EPS and $150.32 million in revenue, leading analysts to maintain a "Moderate Buy" …

Monster Beverage Aktie kaufen oder verkaufen? Prognose 2026

Will Strong Q2 2026 International-Driven Results Change Monster Beverage's (MNST) Margin and Growth Narrative?

In the past week, Monster Beverage Corporation reported Q2 2026 results, with sales rising to US$2,537.47 million and net income to US$584.54 million, alongside higher earnings per share from continuing operations versus a year earlier. These results highlighted especially strong international momentum, as overseas …

ETFs Investing in Molson Coors Beverage Company Class A Stocks

This article lists ETFs that invest in Molson Coors Beverage Company Class A stocks (NY70 on the Frankfurt Stock Exchange). It notes that these funds aim to make stock investing more accessible and offer opportunities with lower risk. The article provides a table for …

Molson Coors Beverage (TAP) Could Be 6% Undervalued Following Q2 Results And Deal Plans

Veradermics Q2 Results: EPS of $(0.58) Beats Estimate

Monster Beverage Stock Split: Why MNST Shares Double, Not Value on August 11